Cargando…
Novel Peptide Vaccine GV1001 Rescues Hearing in Kanamycin/Furosemide-Treated Mice
The cell-penetrating peptide GV1001 has been investigated as an anticancer agent and recently demonstrated anti-oxidant and anti-inflammatory effects. It has shown a protective effect on a kanamycin (KM)-induced ototoxicity mouse model. In the present study, we administered GV1001 at different time...
Autores principales: | Kim, Shin Hye, Jung, Gaon, Kim, Sangjae, Koo, Ja-Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780435/ https://www.ncbi.nlm.nih.gov/pubmed/29403358 http://dx.doi.org/10.3389/fncel.2018.00003 |
Ejemplares similares
-
Outcomes of Peptide Vaccine GV1001 Treatment in a Murine Model of Acute Noise-Induced Hearing Loss
por: Lee, Sang-Yeon, et al.
Publicado: (2020) -
hTERT peptide fragment GV1001 demonstrates radioprotective and antifibrotic effects through suppression of TGF-β signaling
por: Chen, Wei, et al.
Publicado: (2018) -
GV1001 Inhibits the Severity of the Ligature-Induced Periodontitis and the Vascular Lipid Deposition Associated with the Periodontitis in Mice
por: Kim, Sharon Y., et al.
Publicado: (2023) -
The Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating Peptide
por: Kim, Hong, et al.
Publicado: (2016) -
Protective effects of GV1001 on myocardial ischemia-reperfusion injury
por: Chang, Ji-Eun, et al.
Publicado: (2017)